AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27041740 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age and parent insecure attachment
Number of subjects: 43
Study 27041740 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of parents' emotion orientation
Number of subjects: 43
Study 27041740 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual differences in the talk
Number of subjects: 43
Study 25338187 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT/exposure
Number of subjects: 80
Study 25338187 — intervention group
Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 80
Study 21945174 — intervention group
Group type: EXPERIMENTAL
Intervention: dietary intervention with probiotics
Number of subjects: 256
Study 21945174 — intervention group
Group type: COMPARATOR
Intervention: control group (placebo)
Number of subjects: 256
Study 21945174 — intervention group
Group type: EXPERIMENTAL
Intervention: gestational diabetes mellitus
Number of subjects: 256
Study 20307273 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the trial
Number of subjects: 13
Study 20307273 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional altruism
Number of subjects: 13
Study 16481564 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) delivered to the superior temporal cortex
Number of subjects: 0
Study 16481564 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0
Study 15957137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy and high-protein supplementation (an extra 475 kcal and 16.6 g of protein daily; group A; n = 12)
Number of subjects: 39
Study 15957137 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-energy, high-protein supplementation (an extra 67.2 kcal and 16.8 g of protein daily; group B; n = 27)
Number of subjects: 39
Study 15957137 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched well-nourished patients; group C; n = 16)
Number of subjects: 39
Study 12358906 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 1.0 microg/kg
Number of subjects: 66
Study 12358906 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 2.25 microg/kg
Number of subjects: 66
Study 12358906 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 4.5 microg/kg
Number of subjects: 66
Study 12358906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 10444320 — intervention group
Group type: COMPARATOR
Intervention: Written instructions only
Number of subjects: 160
Study 10444320 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral and written instructions
Number of subjects: 160
Study 10444320 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 160
Study 10444320 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability of the test
Number of subjects: 160
Study 7778152 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemether 300 mg on the first day, mefloquine 750 mg at 24 h, and 500 mg at 30 h (group A)
Number of subjects: 159
Study 7778152 — intervention group
Group type: COMPARATOR
Intervention: Oral artemether 300 mg on the first day, mefloquine 750 mg at 24 h, and placebo at 30 h (group B)
Number of subjects: 159
Study 2176795 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (10 micrograms/kg/min for 90 to 120 minutes following skin incision)
Number of subjects: 23
Study 2176795 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diltiazem)
Number of subjects: 23
Study 7425395 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 18
Study 7425395 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate
Number of subjects: 18
Study 30853262 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal (16% total sugar, 26% saturated fat)
Number of subjects: 16
Study 30853262 — intervention group
Group type: COMPARATOR
Intervention: Control meal (8% total sugar, 5% saturated fat)
Number of subjects: 16
Study 30710858 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural gliding
Number of subjects: 48
Study 30710858 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural tensioning
Number of subjects: 48
Study 30710858 — intervention group
Group type: COMPARATOR
Intervention: Neural gliding and tensioning
Number of subjects: 48
Study 28942807 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice a day for 6- to 9-year-olds; 850 mg twice a day for 10- to 17-year-olds)
Number of subjects: 52
Study 28942807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 25476069 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (3 mg, six 2-monthly oral doses over 1 year)
Number of subjects: 240
Study 24382824 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month DAPT arm
Number of subjects: 2420
Study 24382824 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT arm
Number of subjects: 2420
Study 22992312 — intervention group
Group type: EXPERIMENTAL
Intervention: A multifaceted intervention to increase the use of antenatal corticosteroids, including training health providers and distributing kits with dexamethasone.
Number of subjects: 60000
Study 22992312 — intervention group
Group type: COMPARATOR
Intervention: Standard delivery of care in selected populations.
Number of subjects: 60000
Study 19297212 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75mg) and cilostazol (100mg twice daily)
Number of subjects: 19
Study 19297212 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (75mg) and placebo
Number of subjects: 19
Study 16176310 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer preparation package
Number of subjects: 198
Study 16176310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon preparation package
Number of subjects: 198
Study 16176310 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study 14559421 — intervention group
Group type: EXPERIMENTAL
Intervention: Participative standard and performance feedback
Number of subjects: 0
Study 14559421 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive
Number of subjects: 0
Study 14559421 — intervention group
Group type: EXPERIMENTAL
Intervention: Production standards with feedback
Number of subjects: 0
Study 14559421 — intervention group
Group type: COMPARATOR
Intervention: Control group (earlier laboratory study with college students)
Number of subjects: 0
Study 10368452 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m hexamethyl propylenamine oxime (Tc-99m HMPAO) lung clearance study
Number of subjects: 36
Study 8912110 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community principles applied in acute care psychiatric treatment program
Number of subjects: 0
Study 8912110 — intervention group
Group type: COMPARATOR
Intervention: Control units (not specified)
Number of subjects: 0
Study 2069736 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/kg ethanol
Number of subjects: 3
Study 2069736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 7201645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (1.25 mg twice daily) for 3 cycles
Number of subjects: 34
Study 7201645 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 cycle
Number of subjects: 34
Study 7201645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 34
Study 7201645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31453767 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioembolization (RE) in Group A
Number of subjects: 48
Study 31453767 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioembolization (RE) in Group B
Number of subjects: 48
Study 29200372 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 100
Study 29200372 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 100
Study 26296069 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 12
Study 24437213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 347
Study 24437213 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 347
Study 24437213 — intervention group
Group type: EXPERIMENTAL
Intervention: Double AHT (ramipril or losartan + HCT or amlodipine)
Number of subjects: 347
Study 24437213 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (ramipril or losartan + amlodipine + HCT)
Number of subjects: 347
Study 24437213 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 347
Study 21267948 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA intensive behavioral therapeutic program (n = 18)
Number of subjects: 36
Study 21267948 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (n = 18)
Number of subjects: 36
Study 18389193 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.4% glycerol trinitrate
Number of subjects: 0
Study 18389193 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% calcium blocker
Number of subjects: 0
Study 18389193 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection into the internal sphincter
Number of subjects: 0
Study 18389193 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 0
Study 18389193 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissurectomy combined with excision of skin tags and anal papilla
Number of subjects: 0
Study 17319449 — intervention group
Group type: EXPERIMENTAL
Intervention: AVINZA (A-MQD), morphine sulfate extended-release capsules given once a day
Number of subjects: 392
Study 17319449 — intervention group
Group type: EXPERIMENTAL
Intervention: AVINZA (A-MQD)
Number of subjects: 392
Study 17319449 — intervention group
Group type: COMPARATOR
Intervention: OxyContin (O-ER), oxycodone modified-release tablets given twice a day
Number of subjects: 392
Study 14748822 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole suspension (200 mg/5 ml) with a high-fat meal
Number of subjects: 20
Study 14748822 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole suspension (200 mg/5 ml) in fasting state
Number of subjects: 20
Study 14748822 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole suspension (200 mg/5 ml) with a nonfat meal
Number of subjects: 20
Study 14748822 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole tablets (2 x 100 mg) with a high-fat meal
Number of subjects: 20
Study 11321849 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms/day BDP‐AH (n = 98)
Number of subjects: 193
Study 11321849 — intervention group
Group type: COMPARATOR
Intervention: 800 micrograms/day BUD‐DPI (n = 95)
Number of subjects: 193
Study 11321849 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms/day BDP‐AH
Number of subjects: 193
Study 11321849 — intervention group
Group type: COMPARATOR
Intervention: 800 micrograms/day BUD‐DPI
Number of subjects: 193
Study 9140689 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (Tanakan, 320 mg/day, n = 8)
Number of subjects: 15
Study 9140689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 15
Study 7948798 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% bupivacaine with fentanyl (4 micrograms/mL)
Number of subjects: 40
Study 7948798 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% bupivacaine with fentanyl (4 micrograms/mL)
Number of subjects: 40
Study 7948798 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with fentanyl (4 micrograms/mL)
Number of subjects: 40
Study 7948798 — intervention group
Group type: COMPARATOR
Intervention: Plain fentanyl (control group)
Number of subjects: 40
Study 2841591 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (dexamethasone, prednisolone, depot‐ACTH)
Number of subjects: 11
Study 2841591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 11
Study 2841591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phosphate
Number of subjects: 11
Study 2841591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Number of subjects: 11
Study 29040219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact training with calcium and vitamin D supplementation
Number of subjects: 36
Study 29040219 — intervention group
Group type: COMPARATOR
Intervention: Walking at an intense pace (Control)
Number of subjects: 36
Study 27343021 — intervention group
Group type: EXPERIMENTAL
Intervention: Health intervention package (classroom-based health education, hand-held personalized health record, health check)
Number of subjects: 435
Study 27343021 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 435
Study 24297633 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital drainage system (Group A)
Number of subjects: 60
Study 24297633 — intervention group
Group type: COMPARATOR
Intervention: Traditional suction drainage system (Group B)
Number of subjects: 60
Study 22079034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-deprived group
Number of subjects: 31
Study 22079034 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 20845210 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora
Number of subjects: 35
Study 20845210 — intervention group
Group type: COMPARATOR
Intervention: Starch placebo
Number of subjects: 35
Study 19117179 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Tardieu Scale (MTS)
Number of subjects: 30
Study 16651463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (4‐mg tablet)
Number of subjects: 16
Study 14670431 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact ultrasound (US) biometry
Number of subjects: 36
Study 14670431 — intervention group
Group type: COMPARATOR
Intervention: Immersion ultrasound (US) biometry
Number of subjects: 36
Study 11191007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg tid intravenously alone (Group A: 44 patients)
Number of subjects: 84
Study 11191007 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 50 mg tid intravenously plus octreotide 100 micrograms tid subcutaneously for three days (Group B: 40 patients)
Number of subjects: 84
Study 11191007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg tid intravenously alone (Group A)
Number of subjects: 84
Study 11191007 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 50 mg tid intravenously plus octreotide 100 micrograms tid subcutaneously for three days (Group B)
Number of subjects: 84
Study 9187166 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (400 microg)
Number of subjects: 12
Study 9187166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (80 microg)
Number of subjects: 12
Study 9187166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1539469 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake fibreoptic intubation under local anaesthesia (Group B)
Number of subjects: 70
Study 1539469 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation during general anaesthesia (Group A)
Number of subjects: 70
Study 3521416 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest ultrasonography (CU)
Number of subjects: 205
Study 3521416 — intervention group
Group type: COMPARATOR
Intervention: Decubitus roentgenography
Number of subjects: 205
Study 31113646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fructose diet for 2 weeks
Number of subjects: 88
Study 31113646 — intervention group
Group type: COMPARATOR
Intervention: Positive 25 g fructose breath test
Number of subjects: 88
Study 28870461 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0
Study 28870461 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC FcεRIα mRNA expression measured on study entry
Number of subjects: 0
Study 27560098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair transplant
Number of subjects: 122
Study 24612976 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful antimicrobial treatment
Number of subjects: 0
Study 24612976 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22691757 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin chemoradiotherapy supplemented with concurrent gemcitabine and adjuvant gemcitabine/cisplatin
Number of subjects: 515
Study 22691757 — intervention group
Group type: COMPARATOR
Intervention: Concurrent cisplatin chemoradiotherapy
Number of subjects: 515
Study 19438846 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg mesalazine three times daily for 8 weeks
Number of subjects: 20
Study 19438846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17519064 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. (continuous erythropoietin receptor activator) administered subcutaneously at doses determined by previous epoetin therapy (0.4/150, 0.8/150, 1.2/150)
Number of subjects: 137
Study 17519064 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. (continuous erythropoietin receptor activator) administered subcutaneously once monthly (Q4W)
Number of subjects: 137
Study 17519064 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. (continuous erythropoietin receptor activator) administered subcutaneously
Number of subjects: 137
Study 17519064 — intervention group
Group type: COMPARATOR
Intervention: Epoetin therapy administered 1-3 times/week (previous treatment before switching to C.E.R.A.)
Number of subjects: 137
Study 15352962 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 micro g kg(‐1) min(‐1)
Number of subjects: 20
Study 15352962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11192307 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filtration during reperfusion (group I; n = 19)
Number of subjects: 38
Study 11192307 — intervention group
Group type: COMPARATOR
Intervention: No leukocyte filtration during reperfusion (group II; n = 19)
Number of subjects: 38
Study 9709770 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical instillation of 2% dorzolamide hydrochloride
Number of subjects: 25
Study 9709770 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 25
Study 7557064 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine ophthalmic solution (0.5 mgrs/ml), one drop every 12 hours for seven days
Number of subjects: 40
Study 7557064 — intervention group
Group type: COMPARATOR
Intervention: Saline solution drops, one drop every 12 hours for seven days
Number of subjects: 40
Study 2492377 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff model HMO
Number of subjects: 693
Study 2492377 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service plans (with cost-sharing)
Number of subjects: 693
Study 2492377 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 693
Study 1228092 — intervention group
Group type: EXPERIMENTAL
Intervention: Brondiletten retard
Number of subjects: 53
Study 30852136 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose combination chemotherapy with S-1 (20 mg/m2 orally twice daily on days 1–14) and oxaliplatin (100 mg/m2 intravenously on day 1 every 3 weeks)
Number of subjects: 160
Study 30852136 — intervention group
Group type: COMPARATOR
Intervention: Full-dose monotherapy with S-1 (30 mg/m2 orally twice daily on days 1–14 every 3 weeks)
Number of subjects: 160
Study 30852136 — intervention group
Group type: COMPARATOR
Intervention: Full-dose monotherapy with S-1
Number of subjects: 160
Study 30852136 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose combination chemotherapy with S-1 and oxaliplatin
Number of subjects: 160
Study 27338125 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month exercise intervention (regular contact with an exercise physiologist over the phone or home delivered face to face)
Number of subjects: 134
Study 27338125 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study 27338125 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month exercise intervention
Number of subjects: 134
Study 25363733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paricalcitol injection
Number of subjects: 255
Study 25363733 — intervention group
Group type: COMPARATOR
Intervention: Intravenous maxacalcitol injection
Number of subjects: 255
Study 24466598 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention group receiving diabetes-related information and lifestyle modification
Number of subjects: 54
Study 24466598 — intervention group
Group type: COMPARATOR
Intervention: Control group with usual care
Number of subjects: 54
Study 24466598 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention group
Number of subjects: 54
Study 24466598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 21996644 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 11
Study 19816383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic care pathway for advanced therapy in diabetic foot ulceration
Number of subjects: 0
Study 22764248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 0
Study 22764248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16312178 — intervention group
Group type: EXPERIMENTAL
Intervention: QD arm (tenofovir, didanosine, efavirenz)
Number of subjects: 390
Study 16312178 — intervention group
Group type: EXPERIMENTAL
Intervention: QD arm (high didanosine doses)
Number of subjects: 390
Study 16312178 — intervention group
Group type: EXPERIMENTAL
Intervention: QD arm
Number of subjects: 390
Study 16312178 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 390
Study 16312178 — intervention group
Group type: EXPERIMENTAL
Intervention: QD arm (individuals with HIV-1 RNA <400 copies/ml)
Number of subjects: 390
Study 16312178 — intervention group
Group type: COMPARATOR
Intervention: Control arm (individuals with HIV-1 RNA <400 copies/ml)
Number of subjects: 390
Study 16312178 — intervention group
Group type: EXPERIMENTAL
Intervention: QD arm (high vs low didanosine doses)
Number of subjects: 390
Study 12359169 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical k nearest‐neighbor methods
Number of subjects: 32